Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
118.50
+3.02 (+2.62%)
Streaming Delayed Price
Updated: 9:48 AM EDT, Jun 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
99
100
Next >
UK Finance Minister Seeks More Pharma Investment In Exchange For Higher Drug Prices: Report
↗
October 16, 2025
UK finance minister Rachel Reeves told reporters that the country needs to be an attractive place for pharma, including in terms of pricing.
Via
Benzinga
2 Dow Jones Stocks with Exciting Potential and 1 We Brush Off
October 16, 2025
The Dow Jones (^DJI) is home to corporate giants, but size alone doesn’t guarantee success. A few of these companies are struggling with weak fundamentals, paradigm shifts, or poor execution.
Via
StockStory
Topics
Artificial Intelligence
Stocks
Merck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients
↗
October 16, 2025
Merck's KEYNOTE-B96 trial shows Keytruda with chemotherapy improves survival in platinum-resistant recurrent ovarian cancer with a consistent safety profile.
Via
Benzinga
Merck & Co. Inc. (NYSE:MRK) Demonstrates Dividend Strength and Sustainability
↗
October 16, 2025
Discover Merck (MRK), a top dividend stock with a sustainable 3.70% yield, strong profitability, and a solid financial health rating for reliable long-term income.
Via
Chartmill
Merck Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer
October 16, 2025
From
Merck & Co., Inc.
Via
Business Wire
Dow Jones Stumbles with Fractional Dip, Signaling Cautious Market Sentiment Amidst Global Headwinds
October 15, 2025
New York, NY – October 15, 2025 – The Dow Jones Industrial Average (DJIA) experienced a fractional dip today, reflecting a palpable sense of caution pervading market sentiment. While other major...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Government
Merck's New HIV Treatment Works As Well As Top Drug In Late Trials
↗
October 15, 2025
Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 studies with stable weight outcomes.
Via
Benzinga
Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection
October 15, 2025
From
Merck & Co., Inc.
Via
Business Wire
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential
↗
October 14, 2025
Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least $5 billion.
Via
Benzinga
Can $10,000 in Merck Stock Turn Into $50,000 by 2030?
↗
October 14, 2025
The pharmaceutical giant has seen brighter days.
Via
The Motley Fool
Topics
Intellectual Property
Absci's AI Revolution: A New Era for Drug Discovery or a Rocky Road Ahead?
October 13, 2025
Absci (NASDAQ: ABSI), a pioneer in AI-driven drug discovery, is making significant strides with its "Integrated Drug Creation™ Platform," promising to revolutionize how new medicines are brought to...
Via
MarketMinute
Topics
Artificial Intelligence
1 Cash-Producing Stock to Target This Week and 2 That Underwhelm
October 13, 2025
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Via
StockStory
2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk
↗
October 13, 2025
Absci's AI drug development platform is compelling, and its pipeline is promising...but can the company overcome execution hurdles to live up to analyst hype?
Via
MarketBeat
Topics
Artificial Intelligence
Dow Jones Soars on Trump's Tariff Remarks, Signaling Market Volatility Amidst Trade Policy Shifts
October 13, 2025
New York, NY – October 13, 2025 – The Dow Jones Industrial Average has experienced significant upward momentum in recent months, notably jumping by hundreds of points on multiple occasions in early...
Via
MarketMinute
Topics
Economy
Government
Stocks
Tesla To $300? Here Are 10 Top Analyst Forecasts For Monday
↗
October 13, 2025
Via
Benzinga
Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest?
↗
October 13, 2025
Now may be the time to invest in drug companies, as they just slipped the tariff noose.
Via
The Motley Fool
Topics
ETFs
Government
World Trade
Inflation's Shadow Lengthens: September CPI Ignites Fed Caution Amidst Government Shutdown
October 10, 2025
Washington D.C., October 10, 2025 – The financial markets are bracing for impact as the September 2025 Consumer Price Index (CPI) report looms, a critical piece of economic data that promises to shine...
Via
MarketMinute
Topics
Bonds
Economy
World Trade
Global Markets Diverge: Asian Shares Stumble Amid US-China Trade Tensions, While Wall Street Futures Rebound
October 12, 2025
Global financial markets are currently experiencing a significant divergence, with Asian shares facing considerable pressure due to escalating US-China trade tensions, while Wall Street futures have...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Government
UK Weighs 25% Rise In Drug Prices As Pharma Giants Pause Investments
↗
October 10, 2025
UK ministers consider raising NHS drug spending by up to 25% amid pharma investment delays and pressure from US pricing policies.
Via
Benzinga
Pfizer (NYSE:PFE) Marks 348th Consecutive Dividend Payment: A Pillar of Stability Amidst Transformation
October 09, 2025
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Government
Zoetis (NYSE:ZTS) Signals Robust Health with Q4 2025 Dividend Declaration, Bolstering Investor Confidence in Animal Health Sector
October 09, 2025
Parsippany, N.J. – October 9, 2025 – Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today declared a quarterly dividend of $0.50 per share for the fourth quarter of 2025. This...
Via
MarketMinute
Topics
Economy
Zoetis (NYSE:ZTS) Declares $0.50 Q4 2025 Dividend, Signaling Robust Animal Health Market
October 09, 2025
NEW YORK, NY – October 9, 2025 – Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today announced a quarterly dividend of $0.50 per share for the fourth quarter of 2025. This...
Via
MarketMinute
Pfizer's 348th Consecutive Dividend: A Beacon of Stability Amidst Industry Headwinds
October 09, 2025
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE: PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of...
Via
MarketMinute
Topics
Economy
Intellectual Property
Retirement
Behind the Scenes of Merck & Co's Latest Options Trends
↗
October 09, 2025
Via
Benzinga
5 Healthcare Plays Powering the Sector’s Big Comeback
↗
October 09, 2025
After years of lagging, the healthcare sector is showing signs of a turnaround driven by lower rates, policy clarity, and renewed investor interest.
Via
MarketBeat
Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025
October 09, 2025
From
Merck & Co., Inc.
Via
Business Wire
Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Earlier Stages of Disease at ESMO 2025
October 09, 2025
From
Merck Sharp & Dohme
Via
Business Wire
MERCK INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
October 08, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
Merck, Doctors Reject Proposal To Break Up Combined MMR Vaccine
↗
October 07, 2025
Merck and health experts push back against U.S. officials' call to split the MMR vaccine, warning it could delay immunizations and weaken immune response.
Via
Benzinga
How Arcus Biosciences Aims To Take On Merck In Cancer Treatment
↗
October 07, 2025
Shares climbed Tuesday as enthusiasm grows for the biotech company's experimental cancer drug.
Via
Investor's Business Daily
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
